Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRRADIATE-Lung: Pembrolizumab + Radiation in NSCLC
NCT05691829Phase 2Terminated
- Sponsor
- NYU Langone Health
- Start
- Jan 2023
- Primary completion
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by NYU Langone Health. Started Jan 2023; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05691829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05691829.